argenx SE logo

argenx SENASDAQ: ARGX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Netherlands

IPO:

18 May 2017

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$34.36 B
-9%vs. 3y high
97%vs. sector
-vs. 3y high
-vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
84%vs. sector

Price

after hours | Tue, 19 Nov 2024 23:48:01 GMT
$574.54-$4.31(-0.74%)

Dividend

No data over the past 3 years
$573.24 M$607.80 M
$573.24 M$91.41 M

Analysts recommendations

Institutional Ownership

ARGX Latest News

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
globenewswire.com20 November 2024 Sentiment: -

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIA Potential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the decision to continue development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM or myositis), following analysis of topline data from the Phase 2 portion of the study. ALKIVIA will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).

Why Argenx (ARGX) Might be Well Poised for a Surge
zacks.com05 November 2024 Sentiment: POSITIVE

Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
zacks.com05 November 2024 Sentiment: POSITIVE

Here is how argenex SE (ARGX) and Novartis (NVS) have performed compared to their sector so far this year.

argenx to Participate at Upcoming Investor Conferences
globenewswire.com05 November 2024 Sentiment: POSITIVE

November 5, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:

argenx SE (ARGX) Q3 2024 Earnings Call Transcript
seekingalpha.com31 October 2024 Sentiment: NEUTRAL

argenx SE (NASDAQ:ARGX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Beth DelGiacco – Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren – Chief Executive Officer Karl Gubitz – Chief Financial Officer Karen Massey – Chief Operating Officer Conference Call Participants Derek Archila – Wells Fargo Tazeen Ahmad – Bank of America James Gordon – JPMorgan Allison Bratzel – Piper Sandler Myles Minter – William Blair Alex Thompson – Stifel Danielle Brill – Raymond James Amy Li – Jefferies Yaron Werber – TD Cowen Vikram Purohit – Morgan Stanley Charles Pitman-King – Barclays Samantha Semenkow – Citi Gavin Clark-Gartner – Evercore ISI Suzanne van Voorthuizen – Kempen Joel Beatty – Baird Joon Lee – Truist Securities Victor Floc'h – BNP Paribas Xian Deng – UBS Leland Gershell – Oppenheimer Andy Chen – Wolfe Research Rajan Sharma – Goldman Sachs Thomas Smith – Leerink Partners Douglas Tsao – H. C. Wainwright David Seynnaeve – Petercam Emmanuel Papadakis – Deutsche Bank Simon Baker – Redburn Atlantic Operator Good morning.

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
globenewswire.com24 October 2024 Sentiment: POSITIVE

October 24, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update.

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
https://www.globenewswire.com/news-release/2024/10/15/2962892/0/en/argenx-Highlights-Data-Showing-Patient-Impact-Across-Multiple-Immunology-Programs-at-2024-American-Association-of-Neuromuscular-Electrodiagnostic-Medicine-Annual-Meeting-and-Myasth.html15 October 2024 Sentiment: POSITIVE

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response

3 Best Earnings Acceleration Stocks to Buy in a Strong Q4
zacks.com04 October 2024 Sentiment: POSITIVE

With the advent of a strong fourth quarter, it's prudent to invest in stocks exhibiting solid earnings acceleration such as Argenx, Alphatec Holdings and Olin Corporation.

argenx: Myositis Data Could Add Billions In Value
seekingalpha.com24 September 2024 Sentiment: POSITIVE

argenx remains a dominant player in the anti-FcRn market, with Vyvgart approved for gMG, CIDP, and ITP in Japan. The ALKIVIA trial aims to expand Vyvgart's use in myositis, a rare autoimmune disease affecting at least 45,000 people in the U.S. Efgartigimod's FcRn inhibition reduces pathogenic IgG autoantibodies, showing potential across multiple autoimmune diseases.

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
globenewswire.com19 September 2024 Sentiment: POSITIVE

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced publication in The Lancet Neurology of the pivotal ADHERE Study, the largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system.

What type of business is argenx SE?

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

What sector is argenx SE in?

argenx SE is in the Healthcare sector

What industry is argenx SE in?

argenx SE is in the Biotechnology industry

What country is argenx SE from?

argenx SE is headquartered in Netherlands

When did argenx SE go public?

argenx SE initial public offering (IPO) was on 18 May 2017

What is argenx SE website?

https://www.argenx.com

Is argenx SE in the S&P 500?

No, argenx SE is not included in the S&P 500 index

Is argenx SE in the NASDAQ 100?

No, argenx SE is not included in the NASDAQ 100 index

Is argenx SE in the Dow Jones?

No, argenx SE is not included in the Dow Jones index

When was argenx SE the previous earnings report?

No data

When does argenx SE earnings report?

The next expected earnings date for argenx SE is 28 February 2025